10.6084/m9.figshare.c.3672697_D1.v1
Jae-Ho Yoon
Jae-Ho
Yoon
Hee-Je Kim
Hee-Je
Kim
Dae-Hun Kwak
Dae-Hun
Kwak
Sung-Soo Park
Sung-Soo
Park
Young-Woo Jeon
Young-Woo
Jeon
Sung-Eun Lee
Sung-Eun
Lee
Byung-Sik Cho
Byung-Sik
Cho
Ki-Seong Eom
Ki-Seong
Eom
Yoo-Jin Kim
Yoo-Jin
Kim
Seok Lee
Seok
Lee
Chang-Ki Min
Chang-Ki
Min
Seok-Goo Cho
Seok-Goo
Cho
Dong-Wook Kim
Dong-Wook
Kim
Jong Lee
Jong
Lee
Woo-Sung Min
Woo-Sung
Min
Additional file 1: Table S1. of High WT1 expression is an early predictor for relapse in patients with acute promyelocytic leukemia in first remission with negative PML-RARa after anthracycline-based chemotherapy: a single-center cohort study
Springer Nature
2017
Acute promyelocytic leukemia
WT1
FLT3 mutation
Minimal residual disease
2017-01-23 05:00:00
Journal contribution
https://springernature.figshare.com/articles/journal_contribution/Additional_file_1_Table_S1_of_High_WT1_expression_is_an_early_predictor_for_relapse_in_patients_with_acute_promyelocytic_leukemia_in_first_remission_with_negative_PML-RARa_after_anthracycline-based_chemotherapy_a_single-center_cohort_study/4580191
Multivariate analysis in APL patients with CMR. Figure S1. Consort diagram of enrolled patients in this study. Underlined patients were excluded in this study (n=25). Abbreviation: APL, acute promyelocytic leukemia; ATRA, all-trans retinoic acid; CR, complete remission, CMR, complete molecular response; WT1, Wilms tumor 1. Figure S2. Comparison of PML-RARa and WT1 expression levels between relapsed and non-relapsed patients from diagnosis to relapse or 1 year after starting maintenance for non-relapsed patients. (DOCX 152 kb)